The immediate and long-term effects of Shexiang Tongxin Dropping Pills on coronary slow flow

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035167

Enrollment

Unknown

Registered

2020-08-02

Start date

2020-09-01

Completion date

Unknown

Last updated

2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Slow Flow

Interventions

Trial Group:Four tablets of Shexiang Tongxin drop pills were taken under the tongue min and then coronary angiography was performed again, and then 2 tablets of Shexiang Tongxin drop pills were taken

Control group:sublingual placebo 4 capsules 5 min after inclusion of coronary angiography, followed by oral placebo 2 capsules 3 times a day, a total of 3 months.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Clearly diagnosed with coronary slow flow (CSF). 2. Diagnosed with blood stasis syndrome in TCM according to the diagnostic standard issued by the Professional Committee of Promoting Blood Circulation and Removing Blood Stasis of the Chinese Society of Integrated Chinese and Western Medicine in 2016( Diagnosis could be made when fulfilled one of the following threei.Tongue is purplish dark or has ecchymosis, stasis dots; ii.Lips are bluish or dark; iii.Varicose veins of the tongue) 3. Age between 18 to 80 years old, regardless of gender; 4. Agreed to participate in the research and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Have history of myocardial infarction or is diagnosed with acute myocardial infarction 2. Have history of percutaneous coronary intervention 3.Accompanied with heart valve diseases, cardiomyopathies, myocardial bridging, aortic dissection, acute pericarditis, heart failure 4.Accompanied with uncontrolled grade 3 hypertension (systolic blood pressure=180mmHg and/or diastolic blood pressure=110 mmHg), severe arrhythmias, severe liver, kidney, hematopoietic system diseases or malignant tumors, or major mental illnesses 5. Accompanied with severe liver, renal abnormalities (ALT, AST, Scr exceed the upper limit of reference range by 1.5 times.) 6. Allergic to the experimental drugs 7. Known pregnancy or lactation 8. Abnormal thyroid function tests 9. Participates in other clinical study with an investigational product or device during the last 30 days or during the study

Design outcomes

Primary

Measure	Time frame
corrected thrombolysis in myocardial infarction frame count;Cardiac radionuclide score;ET-1;NO;eNOs;iNOs;adropin;IL-6;IL-1;TNF-a;Lp-PLA2;hs-CRP;CD62;CD63;Coagulation function;Blood stasis syndrome score;Immediate change of coronary blood flow;Long-term efficacy;Seattle angina questionnaire;Seattle angina questionnaire;	—

Secondary

Measure	Time frame
Blood routine;Liver and kidney function;Blood lipid;Heart damage (TnI?CK-MB?Myo);NT-proBNP;Urine routine;Stool routine;12-lead electrocardiogram;Color Doppler echocardiography;Rehospitalization;Rehospitalization;	—

Countries

China

Contacts

Public ContactLijing Zhang

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

dzmyyccu@163.com+86 13501214395

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026